

GLAXOSMITHKLINE PLC
Form 6-K
February 21, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 20 February 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc

(the Company)

GlaxoSmithKline plc (the 'Company')

Shares withheld or sold to meet tax liabilities

Following the vesting of awards granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan on 16 February 2017 and as notified on 17 February 2017, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them ('PCA') in Ordinary Shares and in American Depositary Shares (ADSs) of the Company arising from the sale or withholding of Ordinary Shares or ADSs to meet tax liabilities. This notification also includes the sale further to the vesting of awards granted in 2012 to Sir Andrew Witty which were subject to an additional holding period.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2012 and 2014 under the Company's 2009 Performance Share Plan.
 - b) Nature of the transaction
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	9,057
£16.2437	166
£16.2437	55,441
 - d) Aggregated information

Aggregated volume	64,664	Price	£16.2437
-------------------	--------	-------	----------
 - e) Date of the transaction 2017-02-16
 - f) Place of the transaction London Stock Exchange (XLON)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status CEO Designate
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	19,218
 - d) Aggregated information n/a (single transaction)
 - e) Aggregated volume Price
 - f) Date of the transaction 2017-02-16
 - Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing and Supply
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	2014 under the Company's 2009 Performance Share Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.2437 14,957
Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2017-02-16
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
--	---

	ISIN: GB0009252882
b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)	Price(s) Volume(s) £16.2437 32,529
---------------------------	---

Aggregated information	n/a (single transaction)
d) Aggregated volume Price	

e) Date of the transaction	2017-02-16
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- GlaxoSmithKline plc
 American Depository Shares
 a) Description of the financial instrument ('ADSs')
 ISIN: US37733W1053
 The withholding of ADSs to
 meet tax liabilities further to
 the vesting of awards granted
 b) Nature of the transaction in 2014 under the Company's
 2009 Performance Share
 Plan.
 c) Price(s) and volume(s)
 Price(s) Volume(s)
 \$40.57 1,255
 Aggregated information n/a (single transaction)
 d) Aggregated volume Price
 e) Date of the transaction 2017-02-16
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
 b) Position/status President, Global
 Pharmaceuticals
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- Ordinary shares of 25 pence
 each ('Ordinary Shares')
 a) Description of the financial instrument
 ISIN: GB0009252882
 The sale of Ordinary Shares
 to meet tax liabilities for the
 vesting of awards granted in
 b) Nature of the transaction 2014 under the Company's
 2009 Performance Share
 Plan.
 c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.2437 27,371
 d) Aggregated information n/a (single transaction)

- Aggregated volume Price
- e) Date of the transaction 2017-02-16
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr B McNamara
- b) Position/status CEO, Consumer Healthcare
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- GlaxoSmithKline plc
American Depositary Shares ('ADSs')
- a) Description of the financial instrument ('ADSs')
- ISIN: US37733W1053
The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
- b) Nature of the transaction
- | | | |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | \$40.57 | 10,082 |
- Aggregated information n/a (single transaction)
- d) Aggregated volume Price
- e) Date of the transaction 2017-02-16
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	10,738

Aggregated information

d)

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction

2017-02-16

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms C Thomas

b) Position/status

SVP, Human Resources

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	15,320

Aggregated information

d)

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction

2017-02-16

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr P C Thomson
 b) Position/status SVP, Communications & Government Affairs
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.2437 | 7,307 |
- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price
- e) Date of the transaction 2017-02-16
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D E Troy
 b) Position/status SVP & General Counsel
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc American Depositary Shares ('ADSs')
- ISIN: US37733W1053
- b) Nature of the transaction The withholding of ADSs to meet tax liabilities further to the vesting of awards granted

in 2014 under the Company's
2009 Performance Share
Plan.

- | | | |
|-----------------------------|--------------------------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | \$40.57 | 13,035 |
| Aggregated information | n/a (single transaction) | |
| d) Aggregated volume Price | | |
| e) Date of the transaction | 2017-02-16 | |
| f) Place of the transaction | n/a | |

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|----------------------|
| a) Name | Dr P J T Vallance |
| b) Position/status | President, R&D |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
|--|--|

ISIN: GB0009252882

- | | |
|------------------------------|--|
| b) Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. |
|------------------------------|--|

- | | | |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.2437 | 32,996 |

- | | | |
|-----------------------------|------------------------------|--|
| Aggregated information | n/a (single transaction) | |
| d) Aggregated volume Price | | |
| e) Date of the transaction | 2017-02-16 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|----------------------|
| a) Name | Mrs V A Whyte |
| b) Position/status | Company Secretary |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|---------------------|
| a) Name | GlaxoSmithKline plc |
|---------|---------------------|

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
 The sale of Ordinary Shares
 to meet tax liabilities for the
 vesting of awards granted in
 2014 under the Company's
 2009 Performance Share
 Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.2437 2,197

d) Aggregated information n/a (single transaction)

e) Aggregated volume Price

f) Date of the transaction 2017-02-16

Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr K Slaoui

b) Position/status PCA of Dr M M Slaoui
 (Chairman, Global Vaccines)

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument GlaxoSmithKline plc
 American Depositary Shares
 ('ADSs')

b) Nature of the transaction ISIN: US37733W1053
 The withholding of ADSs to
 meet tax liabilities further to
 the vesting of awards granted
 in 2014 under the Company's
 2009 Performance Share
 Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 \$40.57 249

d) Aggregated information n/a (single transaction)

Aggregated volume Price	
e) Date of the transaction	2017-02-16
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 20, 2017

By: VICTORIA WHYTE-----

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc